Regulatory ProfessionalsRegulatory ProfessionalsRegulatory ProfessionalsRegulatory Professionals
  • About Us
    • Our Story
    • Leadership
    • Senior Consultants
  • Services
    • Overview
    • Regulatory Affairs Strategy
    • Electronic Publishing | eCTD
    • Medical and Regulatory Writing
    • Quality Assurance
    • Project Management
    • Electronic Trial Master File | eTMF
  • Resources
    • Blog
    • White Papers
    • News
  • Careers
  • Contact

The FDA Is Ending Its Rare Pediatric Disease Priority Review Vouchers – and Time Is Running Out to Get One

    Home Blog The FDA Is Ending Its Rare Pediatric Disease Priority Review Vouchers – and Time Is Running Out to Get One
    NextPrevious

    The FDA Is Ending Its Rare Pediatric Disease Priority Review Vouchers – and Time Is Running Out to Get One

    By Irene Figari | Blog, Regulatory Affairs | Comments are Closed | 31 July, 2020 | 1

    Between 2010 and 2018, 33.8 percent of the 402 orphan indications approved by the FDA were approved for children only or targeted pediatric diseases.[1] The rare pediatric disease priority review voucher program is one incentive that’s helped to spur research and development in this area with more than 20 vouchers granted to date, but it is set to expire on September 30, 2020.

    However, there is still time for sponsors to request the rare pediatric disease designation that makes a drug eligible for the program. A drug must have rare pediatric disease designation granted by this date and then gain approval for the priority review voucher itself no later than September 30, 2022. 

    The FDA guarantees a 60-day review timeline of rare pediatric disease designation requests when issued alongside a fast track or orphan designation request. As a result, the FDA has announced that it cannot commit to responding by the program deadline for applications received after July 31, 2020. However, sponsors who believe their product is eligible are still encouraged to apply – the sooner, the better. Here’s what you need to know to understand your product’s eligibility and maximize your chance of a successful submission.

    Benefits of the priority review voucher program for rare disease sponsors

    Under the Orphan Drug Act of 1983, companies targeting treatment options for rare diseases are eligible for several additional years of exclusivity in their treatment options without competition from generic alternatives. The priority review voucher program for rare pediatric disease drugs provides an additional benefit by shortening the FDA drug submission review process from the standard ten months to six; however, the priority review process does not require approval within this timeframe.

    Eligible candidates are given two separate vouchers, each of which has priority review: one voucher is used for the drug treating the rare disease while the other one can be used for another indication. While the priority review voucher program for rare pediatric diseases is expiring on September 30, 2020, the vouchers themselves do not expire once granted.

    Who’s eligible for priority review?

    The FDA has published a list of rare diseases that qualify for priority review on its website. For a company to be awarded a priority review voucher, the application must be for a disease that is listed on their website OR another disease that qualifies under the Orphan Drug Act. In addition, the request for a priority review voucher cannot contain an active ingredient that has been approved in any other application. This includes esters and salts of active ingredients.

    Improving your chances of a successful submission

    To improve the chances of a successful submission, companies should ensure the disease they intend to research has been listed on the FDA website, as this will make the approval process easier. It is also important to review other treatments that are being actively researched. In order to be approved, research cannot match another ingredient that is already under development.

    If you are looking to submit a request for rare pediatric disease designation, Regulatory Professionals, A Division of Premier Research, can help. We provide a thorough analysis of the issues and a comprehensive assessment of the regulatory environment to help you enter Agency discussions with strategies to minimize risk and maximize successful negotiations. Contact us today to learn more.


    [1] Kimmel L, Conti RM, Volerman A, Chua KP. Pediatric Orphan Drug Indications: 2010-2018. Pediatrics. 2020;145(4):e20193128. doi:10.1542/peds.2019-3128

    FDA, FDA submissions, orphan drugs, pediatrics, rare disease
    Avatar

    Irene Figari

    More posts by Irene Figari

    Related Post

    • Outsourcing-Pharma.com: Holistic Approach Benefits Drug Development

      By Sameena Sharif | Comments are Closed

      Professionals focused on drug development are charged with making the most of their resources, maximizing the value of their work, and bringing effective products to market as quickly as they can without compromising quality orRead more

    • 5 Tips to Avoid an IND Clinical Hold: Regulatory Guidance and Insights

      By Aurora Sosa | Comments are Closed

      A clinical hold from the U.S. Food and Drug Administration can significantly prolong the time and increase the cost of drug development, which is particularly concerning for emerging/small biotech and specialty pharma companies. In thisRead more

    • Creating a Compliant eCTD: Avoiding Common Regulatory and Technical Pitfalls on the Path to Submission

      By Valerie Bright | Comments are Closed

      The Electronic Common Technical Document (eCTD) is the standard format for submitting applications, amendments, supplements, and reports to the U.S. Food & Drug Administration (FDA). The eCTD harmonizes the regulatory review process for global drugRead more

    • COVID-19 Update: What Sponsors Need to Know About the New FDA Guidance

      By Nach Davé | Comments are Closed

      With the emergence of the COVID-19 pandemic, we are all experiencing uncertainty. This uncertainty is impacting our personal lives, and it’s also impacting and reshaping the critical research biotech and specialty pharma companies are conducting.Read more

    • Statistical Considerations for FDA COVID-19 Guidance

      By Shari Medendorp | Comments are Closed

      In response to the newly released U.S. Food and Drug Administration (FDA) guidance on COVID-19, the Statistics Department at Premier Research has committed to highlight specific and necessary actionable considerations that directly address key FDARead more

    NextPrevious

    Recent Posts

    • Beware of Underestimating the Value of a Pre-NDA Meeting
    • Outsourcing-Pharma.com: Holistic Approach Benefits Drug Development
    • 5 Tips to Avoid an IND Clinical Hold: Regulatory Guidance and Insights
    • The FDA Is Ending Its Rare Pediatric Disease Priority Review Vouchers – and Time Is Running Out to Get One
    • Creating a Compliant eCTD: Avoiding Common Regulatory and Technical Pitfalls on the Path to Submission

    Categories

    • Blog
    • CMC
    • COVID-19
    • FDA
    • INTERACT Meeting
    • News
    • Podcast
    • Regulatory Affairs
    • White Papers
    January 2021
    M T W T F S S
    « Nov    
     123
    45678910
    11121314151617
    18192021222324
    25262728293031

    Headquarters

    8000 Jarvis Ave.
    Suite 100
    Newark, CA 94560

    North Carolina

    One Park Drive, Suite 150
    Box 13608
    Research Triangle Park,
    NC 27709

    San Diego

    Aventine Building
    8910 University Center Lane
    Suite 400 San Diego, CA 92122

    United Kingdom

    250 South Oak Way
    Green Park
    Reading, Berkshire, RG2 6UG

    Australia

    Premier Research Australia Pty Ltd.
    Ground Floor, 23 Milton Parade
    Malvern VIC 3144

    • Home
    • About Us
    • Services
    • Cookie Policy
    • Privacy Notice
    • Contact
    Copyright 2020 Regulatory Professionals | All Rights Reserved
    • About Us
      • Our Story
      • Leadership
      • Senior Consultants
    • Services
      • Overview
      • Regulatory Affairs Strategy
      • Electronic Publishing | eCTD
      • Medical and Regulatory Writing
      • Quality Assurance
      • Project Management
      • Electronic Trial Master File | eTMF
    • Resources
      • Blog
      • White Papers
      • News
    • Careers
    • Contact
    Regulatory Professionals
    XWe use cookies (and equivalent technologies) to collect and analyze information on our Website’s performance and to enable the Website to function. Cookies also allow us and third parties to tailor the ads you see when you visit our Website and other third party websites in the same online network, including social networks. By clicking ‘AGREE', you agree to these uses of cookies. If you do not agree or if you would like more information, you can manage your cookie preferences by clicking on 'Cookie Settings'. Cookie Policy REJECTAGREECookie Settings
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled

    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

    Non Necessary

    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

    Save & Accept